Nicholas P. Restifo

National Institutes of Health — United States

Immunology and Microbiology · Life Sciences

150h-index95.7kcitations674works5.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(372), CAR-T cell therapy research(355), Immune Cell Function and Interaction(206), Cancer Immunotherapy and Biomarkers(142), T-cell and B-cell Immunology(136)

Publications671 total

T cells lead the charge against solid tumors
Nature Cancer·2024· 6 cited
IMMClock reveals immune aging and T cell function at single-cell resolution
2024· 1 citedOpen Access
LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling
Signal Transduction and Targeted Therapy·2024· 14 citedOpen Access
Synthetic soldiers: Turning T cells into immortal warriors
The Journal of Experimental Medicine·2024· 4 citedOpen Access
Abstract 6593: Rejuvenation of tumor-infiltrating lymphocytes (TIL): A novel strategy to revitalize TIL antitumor function for cell therapy
Cancer Research·2024· 2 cited
Abstract A041: Rejuvenation: Innovative technology to improve T-cell antitumor properties through partial reprogramming
Cancer Immunology Research·2023
393 Rejuvenation of tumor-infiltrating lymphocytes (TIL) through partial reprogramming
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Figure S4 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
FIGURE 6 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
Figure S3 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
FIGURE 5 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
FIGURE 1 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
Figure S3 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
FIGURE 3 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
Figure S2 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
Figure S1 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
TABLE 1 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
FIGURE 1 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
Figure S4 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
FIGURE 2 from Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells
2023Open Access
page 1 of 34Next →

Frequent Co-authors

Steven A. Rosenberg(28), Mark E. Dudley(14), Richard M. Sherry(14), James Chih‐Hsin Yang(11), Udai S. Kammula(11), Luca Gattinoni(11), Douglas C. Palmer(11), Christopher A. Klebanoff(10), John R. Wunderlich(9), Zhiya Yu(9), Paul F. Robbins(8), Marybeth S. Hughes(8), Paul A. Antony(8), Suzanne L. Topalian(7), James C. Yang(6), Sharon Mavroukakis(6), Carolyn M. Laurençot(6), Steven E. Finkelstein(6), Pawel Muranski(6), Kathleen E. Morton(5)